The Partner State Key Laboratory of Chirosciences at the Department of Applied Biology and Chemical Technology (ABCT) of The Hong Kong Polytechnic University (PolyU) discovered a newly emerged superbug, hyper-resistant and hypervirulent Klebsiella pneumoniae, which may cause untreatable and fatal infections in relatively healthy individuals and will pose enormous threat to human health.
Prof. Chen Sheng, Professor of ABCT, collaborating with Prof. Rong Zhang from the Second Affiliated Hospital of Zhejiang University, conducted an investigation into a fatal outbreak of pneumonia in the Second Affiliated Hospital of Zhejiang University in China in February 2016. The study involved five patients who underwent surgical operation for multiple-trauma. All of them were later infected in the intensive care unit (ICU) and developed severe pneumonia, and eventually died of septicaemia and multiple organ failure. The causative agent of these five patients was found to be a carbapenem-resistant K. pneumoniae (CRKP) strain, a type of previously-defined superbug. Furthermore, these CRKP strains are also hypervirulent and belong to ST11 type of CRKP, the most prevalent and transmissible CRKP strains in Asia. As these strains simultaneously exhibit the features of hyper-resistance, hypervirulence and high transmissibility, they can be considered a real superbug known as ST11 CR-HvKP (ST11 carbapenem-resistant hypervirulent K. pneumoniae).
ST11 K. pneumoniae strains proliferate in the gastrointestinal tract (GI tract) of human and animals and may cause opportunistic infections such as pneumonia in clinical settings. These strains, after acquiring plasmid encoding a carbapenemase gene, become resistant to the carbapenem antibiotics and caused untreatable or hard-to-be treated infections, therefore defined as superbug. These superbug strains could further evolve to become ST11 CR-HvKP through acquisition of the hypervirulence plasmids. The ST11 CR-HvKP strains do not only infect lungs and cause pneumonia, but also invade the bloodstream and other internal organs. Due to its hypervirulence and phenotypic resistance to commonly used antibiotics, ST11 CR-HvKP strains may cause untreatable and fatal infections in relatively healthy individuals with normal immunity.
ST11 CR-HvKP strains possess a mucoid outer layer, which enables them to stick to various materials, such as the surface of medical devices and tubing as well as other surfaces in the ICU. The transmission route is not clear yet, but our data suggest that medical equipment such as ventilator and different catheters might be transmitting these new superbug strains. Human-to-human transmission may also be possible, mainly in hospital settings. Improved infection prevention and control policy in hospital seems to be effective to control further transmission of this superbug in the ICU. Novel strategies must be devised to prevent ST11 CR-HvKP from proliferating extensively in the human intestinal tract where they were detected. ST11 CR-HvKP can easily be detectable by the Polymerase chain reaction (PCR) method, targeting specific resistance and virulence genes. The study showed that the use of colistin (the last resort drug for carbapenem-resistant enterobacteriaceae infections) alone or in combination with other drugs were not very effective in treating infections caused by ST11 CR-HvKP. Ceftazidime/avibactam may be the effective antibiotic, but ST11 CR-HvKP may develop resistance to this antibiotic very quickly based on the clinical data from the USA.
Prevalence of ST11 CR-HvKP strains in Hong Kong is currently unknown. Two studies conducted in Hong Kong have shown that mortality rate due to K. pneumoniae-mediated bloodstream infections was high, reaching 20% and 32% respectively. We plan to collaborate with clinicians in local hospitals to investigate the proportion of clinical K. pneumoniae isolates that belong to HvKP or CR-HvKP, and characterize their genetic features.
Learn more:Â PolyU discovers a newly emerged superbug — hyper-resistant and hypervirulent Klebsiella pneumoniae
The Latest on: Klebsiella pneumoniae
- Newborns face increasing risk as antibiotics fail in the face of infectionon May 9, 2022 at 7:42 am
Multi-drug resistant bacterial infections coupled with huge population growth and rapid urbanisation are among factors adding to Africa's neonatal sepsis burden.The number of newborn babies dying from ...
- Advancements in Personalized Healthcare through Regenerative Medicine to Drive the Antibiotic Resistance Market At A CAGR Of 4%on May 6, 2022 at 8:32 am
The global antibiotic resistance market is expected to go great guns in the next 10 years. It is slated to reach US$ 12.6 Mn by the year 2031. The CAGR would be 4%. With mixed reality in the foray, ...
- Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical Patternson May 5, 2022 at 5:00 pm
A prospective study of consecutive patients with community-acquired K. pneumoniae bacteremia was performed in 12 hospitals. (1) The study period was January 1, 1996, to December 31, 1997.
- Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical Patternson May 3, 2022 at 5:00 pm
Two hundred two (44.4%) of 455 episodes of K. pneumoniae bacteremia during the study period were community-acquired cases. The percentage of cases of K. pneumoniae bacteremia that were community ...
- Asia-Pacific Market For Carbapenem-Resistant Enterobacteriaceae Testing Is Expected To Expand During 2022-2032on May 2, 2022 at 2:15 am
Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii. According to The Centers for Disease Control ...
- St. Louis vaccine startup expands C-suite and gets new nameon April 19, 2022 at 2:45 pm
Founded in 2017, Omniose has developed a technology platform it is using to develop vaccines for Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. Its research operations ...
- Silver nitrate can re-sensitize the last-line antimicrobial colistin in combination therapy against superbugson April 14, 2022 at 6:25 am
Klebsiella pneumoniae, Escherichia coli, Shigella and Acinetobacter baumannii. Unfortunately, the efficacy of colistin has been seriously compromised in the regular treatment of lethal bacterial ...
- Capsule Stainon May 19, 2021 at 11:31 am
Make a light smear from the milk culture of Klebsiella pneumoniae. Take 1-2 loopfuls and spread it throughout the circle. Do not dilute the culture with water. Air dry thoroughly. Make certain that ...
- Drugs & Medications A-Zon December 17, 2020 at 8:05 pm
Considering taking medication to treat hospital-acquired pneumonia due to klebsiella pneumoniae? Below is a list of common medications used to treat or reduce the symptoms of hospital-acquired ...
- Drugs & Medications A-Zon August 13, 2018 at 8:35 am
Considering taking medication to treat bacterial pneumoniae caused by klebsiella pneumoniae? Below is a list of common medications used to treat or reduce the symptoms of bacterial pneumoniae ...
via Google News and Bing News